CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events
Item8.01 Other Events.
On April13, 2017, CRISPR Therapeutics AG issued a press release
entitled CRISPR Therapeutics, Intellia Therapeutics, Caribou
Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S.
Patent Board Decision. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
Item9.01.Financial Statements and Exhibits.
(d)Exhibits:
The following exhibits shall be deemed to be furnished, and not
filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press Release by CRISPR Therapeutics AG, dated April13, 2017 |
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States. CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Recent Trading Information
CRISPR THERAPEUTICS AG (NASDAQ:CRSP) closed its last trading session up +0.51 at 19.41 with 20,543 shares trading hands.